Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of ABBV-155 alone and with taxane therapy in relapsed or refractory solid tumors
jRCT2080225314Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of mirzotamab clezutoclax in Nonhematologic neoplasms, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and 1 more (4 arms), sponsored by AbbVie Inc. Started Aug 2020; status: completed.
02
Drugs
mirzotamab clezutoclax
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on jRCT2080225314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225314.